GlassScriptPhysician profile
Mimi J Biswas
NPI 1518970755
$4,531.49
in general payments reported to CMS, 2019-2025
30 companies · $475 in 2025
The $475 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $580 · 2020: $449 · 2021: $187 · 2022: $948 · 2023: $1,473 · 2024: $419 · 2025: $475.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,368.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,367.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $988.45 | 2019-2025 | Lifevest |
| Merck Sharp & Dohme LLC | $630.42 | 2022-2025 | Verquvo, Capvaxive |
| Abbott Laboratories | $489.36 | 2020-2024 | Thoratec Heartmate 3 Lvas Implant Kit, Mitraclip, Cardiomems |
| Abiomed | $250.85 | 2022-2023 | Impella |
| Novartis Pharmaceuticals Corporation | $215.69 | 2019-2024 | |
| Medtronic, INC. | $182.46 | 2023 | Linq II, Onyx Frontier |
| Boehringer Ingelheim Pharmaceuticals, INC. | $181.07 | 2020-2025 | Jardiance |
| Amgen INC. | $128.62 | 2019-2025 | Repatha, Repatha |
| Janssen Scientific Affairs, LLC | $123.78 | 2023 | Xarelto |
| Kiniksa Pharmaceuticals, LTD. | $120.09 | 2022-2023 | Arcalyst |
| E.R. Squibb & Sons, L.L.C. | $103.38 | 2022-2025 | Eliquis, Camzyos |
| Arineta, INC | $99.02 | 2021 | |
| Medtronic Vascular, INC. | $97.75 | 2019 | |
| Pfizer INC. | $95.32 | 2019 | |
| Boston Scientific Corporation | $94.17 | 2020-2025 | Watchman Access System |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cvrx, INC. | $88.18 | 2022 | |
| Atricure, INC. | $78.94 | 2023-2024 | |
| Biotronik INC. | $73.20 | 2019 | |
| Sanofi-Aventis U.S. LLC | $64.84 | 2019-2020 | |
| Gilead Sciences, INC. | $63.41 | 2019 | |
| Scpharmaceuticals INC. | $55.17 | 2025 | |
| La Jolla Pharmaceutical Company | $50.35 | 2022 | |
| Lexicon Pharmaceuticals, INC. | $49.44 | 2024 | |
| Irhythm Technologies, INC. | $47.14 | 2022-2023 | Zio Xt Patch |
| Regeneron Healthcare Solutions, INC. | $40.55 | 2019 | |
| Janssen Pharmaceuticals, INC | $29.99 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $28.62 | 2019-2024 | Farxiga |
| Heartflow, INC. | $28.54 | 2022 | |
| Smith+Nephew, INC. | $20.08 | 2022 | |
| Amarin Pharma, INC. | $12.61 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mimi Biswas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.